Beiersdorf and Insilico join forces on AI research

Companies collaborate to discover novel, safe bioactive ingredients for skin indications – applying AI to advanced cosmetics: An important part of the Longevity ecosystem.

Skin care giant Beiersdorf and AI firm Insilico Medicine have announced a collaboration to jointly discover novel, safe bioactive ingredients for a specific skin indication to serve as the basis for developing appropriate skincare products. Hamburg-based Beiersdorf is best known for its Nivea consumer skincare brand.

“As part of our Open Innovation culture, we are always looking for new technologies and partners with strengths that complement ours,” said Dr. May Shana’a, Senior Corporate Vice President, Research and Development, at Beiersdorf. “We are delighted to now be working with Insilico Medicine as a veritable expert when it comes to artificial intelligence. We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biological effects in silico. This enables us to cater even better to the consumers’ as yet unmet skincare needs.”

As part of the collaboration, new molecules for a specific skin indication are to be generated and analyzed using next-generation artificial intelligence developed by Insilico.

“We firmly believe there is a great potential in this collaboration,” said Alex Zhavoronkov, CEO of Insilico Medicine. “We worked with many consumer companies in the past and in my opinion, Beiersdorf became an undisputed leader in the area of skin research as well as in digital technologies in recent decades. We are delighted that they have recognized the potential of artificial intelligence early on and hope to demonstrate the power of AI going forward in our collaboration.”

We believe that Advanced Cosmetics will become an important part of the Longevity ecosystem, and the sector was included by Aging Analytics Agency as part of its 2019 Longevity Industry Landscape Overview. Forthcoming Longevity-centric developments in the world of cosmetics are expected to include rejuvenated stem cell facelifts, personalised stem cell creams and prognostics, and cosmetic nutraceuticals targeted at the hallmarks of aging.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.

Amazon and K4Connect demonstrate scalability for agetech

Covid-19 has been difficult for everyone, but particularly for people over the age of 65 who may spend months shut away from loved ones...

“Avoid the use of DQ as a senolytic therapy”

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation today published its latest risk-benefit analysis, which explores...